secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001104659-25-029974
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents Q4 product rev $9.2M (+25% YoY); FY rev $35.6M (+15%); expects FDA decision 2025
--------------------------------------------------------------------------------

- Q4 product revenue $9.2M (+25% YoY); product gross margin 71%; operating loss improved 61% to $3.7M.
- Adjusted net loss improved 78% to $1.7M ($0.03 per share) vs $7.8M loss in Q4 2023.
- Full year product revenue $35.6M (+15%); net loss $20.7M ($0.38 per share); adjusted net loss $12.7M ($0.23 per share).
- Cash $9.8M at Dec 31; pro forma $17M after $7.3M rights offering net proceeds.
- Expects DrugSorb-ATR FDA & Health Canada decisions in 2025; Q1 2025 product sales to decline due to Germany restructure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465925029974/0001104659-25-029974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465925029974/tm2510844d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-029974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer